Linagliptin use in older individuals with type 2 diabetes

Linagliptin use in older individuals with type 2 diabetes

Richard E Pratley1–31Florida Hospital Diabetes Institute, 2Translational Research Institute for Metabolism and Diabetes, 3Sanford-Burnham Medical Research Institute, Orlando, FL, USAAbstract: Older people have the highest prevalence of type 2 diabetes mellitus (T2DM) of a...

Full description

Bibliographic Details
Main Author:	Pratley RE
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-07-01
Series:	Clinical Interventions in Aging
Subjects:	DPP-4 inhibitors older individuals
Online Access:	https://www.dovepress.com/linagliptin-use-in-older-individuals-with-type-2-diabetes-peer-reviewed-article-CIA

Similar Items

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

A Localized Painful Rash Induced by Linagliptin in a Patient with type 2 Diabetes
by: İsmail Yıldız, et al.
Published: (2019-05-01)

A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19
by: Ran Abuhasira, et al.
Published: (2021-12-01)

Prescriptions of newer glucose regulating agents in older hospitalized patients with type 2 diabetes A retrospective cohort study
by: Drs. Merel L.J.M. Janssen, et al.
Published: (2023-10-01)

Linagliptin: a thorough characterization beyond its clinical efficacy
by: Maria Angela eSortino, et al.
Published: (2013-02-01)

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
by: Johansen Odd, et al.
Published: (2012-01-01)

Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
by: Yan-Rong Li, et al.
Published: (2018-01-01)

Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice
by: Nikita Nirwan, et al.
Published: (2022-07-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01)

Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans
by: Sri Nagarjun Batchu, et al.
Published: (2020-08-01)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar CS, et al.
Published: (2013-04-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB
by: Sura Al Zoubi, et al.
Published: (2018-12-01)

Treatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medications
by: Tat'yana Morgunova, et al.
Published: (2016-11-01)

Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor
by: Tomoko Okuyama, et al.
Published: (2020-10-01)

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis
by: Maneesha Khalse, et al.
Published: (2020-01-01)

DPP4 Regulates the Th17/IL-17 Axis and Accelerates Epithelial Mesenchymal Transition to Promote Ovalbumin-Induced Asthma in Female C57BL/6J Mice
by: Linqiao Li, et al.
Published: (2023-12-01)

Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial
by: Norbert J. Tripolt, et al.
Published: (2018-05-01)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
by: Matthew P. Gilbert, et al.
Published: (2020-04-01)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
by: Ghosh S, et al.
Published: (2016-11-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
by: Eun Yeong Choe, et al.
Published: (2014-06-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
by: Makoto Fujiwara, et al.
Published: (2022-03-01)

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
by: Xu Liu, et al.
Published: (2021-09-01)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
by: Cobble Michael E, et al.
Published: (2012-01-01)

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
by: Hershon KS
Published: (2016-05-01)

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
by: Anna A. Mosikian, et al.
Published: (2018-11-01)

Hypoglycemic agents and prognostic outcomes of chronic kidney disease patients with type 2 diabetes
by: Kyaw Kyaw Hoe, et al.
Published: (2023-06-01)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
by: Yu H, et al.
Published: (2017-07-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
by: Mei-Tzu Wang, et al.
Published: (2017-07-01)